COMPOSITION / SINGLE
SLU-PP-332
5MGImportant medical and research notice
This content is intended for educational and research reference only and does not constitute medical advice, diagnosis, or treatment. Experimental compounds are for research use only and are not for human consumption. Always consult qualified healthcare providers before starting any therapy.
Research Overview
A pan-agonist of the estrogen-related receptors (ERRα/β/γ), studied in preclinical exercise-mimetic and mitochondrial research.
Available Strengths
- 5MG (SLU5)
Research Protocol
Reference schedule (dose shown per injection, twice daily)
| Period | Dose | U-100 units | Volume |
|---|---|---|---|
| Weeks 1–2 | 0.625 mg | 37.5 | 0.375 mL |
| Weeks 3–8 | 1.25 mg | 75 | 0.75 mL |
Reconstitution
Water volume3 mLConcentration1.67 mg/mLAdministrationIntraperitoneal in the cited preclinical/animal research — no human trials have been conducted as of the source's last update.FrequencyTwice daily in the cited animal-model protocolCycle length8 weeks in the cited animal-model research.
≈1.67 mg/mL once reconstituted
- Draw 3.0 mL of bacteriostatic water per 5 mg vial.
- Inject slowly along the vial wall; swirl gently until dissolved.
Research context
Described in murine research as enhancing mitochondrial function and fatty-acid oxidation through ERR pathway activation.
Storage
−20°C. 2–8°C, avoid freeze-thaw cycles.
Research Notes
- For educational and research reference only. Not medical advice and not intended for unsupervised human use.
- All available evidence for this compound is preclinical (animal-model); no human dosing route or schedule is established. The intraperitoneal route above reflects the research model only and is not a subcutaneous human-use recommendation.
References
Source reference: PeptideDosages.com · 2026-08-18 · Exact strength match with the cited source